A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia

• In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months

• Stable symptoms of schizophrenia for at least 3 months.

Exclusion Criteria:

• Subjects with a psychiatric disorder other than schizophrenia

• Substance dependence or abuse

• Women who have child bearing potential.